{
    "root": "f56140f5-edaf-4ede-a7a4-4506caaca572",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tadalafil",
    "value": "20250327",
    "ingredients": [
        {
            "name": "TADALAFIL",
            "code": "742SXX0ICT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_71940"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "tadalafil tablets phosphodiesterase 5 ( pde5 ) inhibitor indicated treatment : erectile dysfunction ( ed ) ( 1.1 ) signs symptoms benign prostatic hyperplasia ( bph ) ( 1.2 ) ed signs symptoms bph ( ed/bph ) ( 1.3 ) tadalafil tablets used finasteride initiate bph treatment , recommended 26 weeks ( 1.4 ) .",
        "doid_entities": [
            {
                "text": "erectile dysfunction (DOID:1875)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1875"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "split tadalafil tablets ; entire dose taken .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "tadalafil tablets , usp supplied follows : 5 mg pale yellow , oval-shaped , film-coated tablets , debossed \u2018 09 \u2019 one side plain side . bottles 30 ndc 0480-2309-56 10 mg pale yellow , oval-shaped , film-coated tablets , debossed \u2018 10 \u2019 one side plain side . bottles 30 ndc 0480-2310-56 20 mg pale yellow , oval-shaped , film-coated tablets , debossed \u2018 11 \u2019 one side plain side . bottles 30 ndc 0480-2311-56",
    "adverseReactions": "tadalafil tablets patients using form organic nitrate contraindicated . tadalafil tablets shown potentiate hypotensive effect nitrates ( 4.1 ) . history known serious hypersensitivity reaction tadalafil adcirca \u00ae ( 4.2 ) . guanylate cyclase ( gc ) stimulators , riociguat ( 4.3 ) .",
    "indications_original": "Tadalafil tablets are a\u00a0phosphodiesterase\u00a05\u00a0(PDE5) inhibitor indicated\u00a0for\u00a0the treatment of: erectile\u00a0dysfunction\u00a0(ED) ( 1.1 ) the signs and\u00a0symptoms of\u00a0benign\u00a0prostatic\u00a0hyperplasia\u00a0(BPH) ( 1.2 ) ED and\u00a0the\u00a0signs and\u00a0symptoms of\u00a0BPH (ED/BPH) ( 1.3 ) If\u00a0tadalafil tablets\u00a0are\u00a0used\u00a0with finasteride\u00a0to\u00a0initiate\u00a0BPH\u00a0treatment,\u00a0such\u00a0use\u00a0is recommended\u00a0for up\u00a0to\u00a026\u00a0weeks ( 1.4 ).",
    "contraindications_original": "Do not split tadalafil tablets; entire dose should be taken.",
    "warningsAndPrecautions_original": "Tadalafil tablets, USP are supplied as follows: \n                        5 mg pale yellow, oval-shaped, film-coated tablets, debossed with \u201809\u2019 on one side and plain on the other side.\n                        Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 0480-2309-56\n                        10 mg pale yellow, oval-shaped, film-coated tablets, debossed with \u201810\u2019 on one side and plain on the other side.\n                        Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 0480-2310-56\n                        20 mg pale yellow, oval-shaped, film-coated tablets, debossed with \u201811\u2019 on one side and plain on the other side.\n                        Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 0480-2311-56",
    "adverseReactions_original": "Administration\u00a0of tadalafil tablets\u00a0to\u00a0patients\u00a0using\u00a0any\u00a0form\u00a0of\u00a0organic nitrate\u00a0is contraindicated.\u00a0Tadalafil tablets were shown to\u00a0potentiate\u00a0the hypotensive\u00a0effect\u00a0of nitrates ( 4.1 ). History of known serious hypersensitivity reaction to tadalafil or\u00a0ADCIRCA \u00ae ( 4.2 ). Administration\u00a0with\u00a0guanylate\u00a0cyclase\u00a0(GC)\u00a0stimulators, such\u00a0as riociguat\u00a0( 4.3 ).",
    "drug": [
        {
            "name": "Tadalafil",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_71940"
        }
    ]
}